Physician profile
Scott Osmun
NPI 1164623930
$610.79
in general payments reported to CMS, 2019-2025
15 companies · $83.66 in 2025
The $83.66 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $61.28 · 2021: $78.22 · 2022: $50.14 · 2023: $55.74 · 2024: $104 · 2025: $83.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $112.91 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $96.61 | 2019-2022 | |
| Abbvie INC. | $65.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $52.42 | 2019 | |
| Becton, Dickinson and Company | $38.40 | 2022-2025 | Bd Max System, Bd Max Instrument |
| Optumhealth Care Solutions, LLC | $28.64 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Aspira Women'S Health INC | $23.71 | 2023 | Ova1 |
| Evofem Biosciences, INC. | $23.39 | 2021 | |
| Hologic Sales and Service, LLC | $21.49 | 2025 | Novasure |
| Aesculap, INC. | $19.07 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.19 | 2019 | |
| Pfizer INC. | $16.77 | 2024 | |
| Coopersurgical, INC. | $15.73 | 2023 | Endosee |
| Avion Pharmaceuticals | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Osmun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.